Objective-oriented planification in the treatment of hypercholesterolemia;Planificación del tratamiento de la hipercolesterolemia orientada a la obtención de objetivos

Medicina Clinica

Volumn 124, Issue 3, 2005, Pages 108-110

  Masana, Lluís ^a   Plana, Nuria ^a  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

CARDIOVASCULAR RISK; DIABETES CONTROL; EVIDENCE BASED MEDICINE; HYPERCHOLESTEROLEMIA; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MONOTHERAPY; PRESCRIPTION; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; SPAIN; TREATMENT INDICATION; TREATMENT PLANNING;

EID: 14344265963     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13070853     Document Type: Article

References (16)

1. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
2. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987-1003.
3. Haffner SM; American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care. 2004;27 Supl 1:S68-71.
4. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation. 2000;102:1014-9.
5. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52:1210-4.
6. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al, and the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504.
7. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-96.
8. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-39.
9. Brotons C, Royo-Bordonada MA, Alvarez-Sala L, Armario P, Artigao R, Conté P, et al. Comité Español Interdisciplinario para la Prevencion Cardiovascular. Adaptación española de la guía europea de prevención cardiovascular. Rev Esp Salud-Publica. 2004;78:435-8.
10. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-7.
11. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9.
12. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet. 2001;357:995-1001.
13. De Velasco JA, Cosin J, López-Sendon JL, De Teresa E, De Oya M, Sellers G. Nuevos datos sobre la prevención secundaria del infarto de miocardio en España. Resultados del estudio PREVESSE II. Rev Esp Cardiol. 2002; 55:801-9.
14. García Ruiz FJ, Marín Ibáñez TT, Pérez-Jiménez F, Pintó X, Mocea G, Ahumada C, et al. Current lipid management and low cholesterol goal attainment in common daily practice in Spain. Pharmaooeconomics. 2004;22 Supl 3:1-12.
15. Edwards JE, Moore RA. Statins in hypercholesterolemia: a dose-specific meta-analysis of lipid changes in randomized, double blind trials. BMC Family Practice [revista electrónica] 2003 [citado 10-11-2004];4:18-37. Disponible en: http://www.biomedcentral.com/1471-2296/4/18
16. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of Atorvastatin versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in patients with hypercholesterolemia (The CURVES Study). Am J Cardiol. 1998;81:582-7.